NewAmsterdam Pharma NAMS
NASDAQ NAMS
$20.39 +1.21 (+6.32%)
As of: Nov 11, 2026 · 1:01 PM EST

NewAmsterdam Pharma (NAMS) Net Equity Issued and Repurchased (2023 - 2026)

Updated

NewAmsterdam Pharma (NAMS) posted Net Equity Issued and Repurchased of $11.04 million for Q2 2026, up 222.4% from $3.43 million a year earlier but down 0.2% from the prior quarter.

Analysis

NewAmsterdam Pharma (NAMS) Net Equity Issued and Repurchased (2023 - 2026) Analysis & Trends

For the trailing twelve months through Jun 30, 2026, Net Equity Issued and Repurchased at NewAmsterdam Pharma was $41.68 million, up 215.8% year-over-year; for FY2025, it came in at $31.11 million, up 100.3% from FY2024.

  • Annual Net Equity Issued and Repurchased shows a four-year compound annual growth rate of -22.2% (FY2021 to FY2025).
  • In prior years, NewAmsterdam Pharma's Net Equity Issued and Repurchased was $15.53 million in FY2024 (+74.2%), $8.91 million in FY2023 (-96.2%), $234.6 million in FY2022 (+177.0%) and $84.7 million in FY2021.
  • Quarterly Net Equity Issued and Repurchased has run from a low of $58,000 in Q3 2024 to a high of $13.68 million in Q4 2025 over five years.
  • On a year-over-year basis, Net Equity Issued and Repurchased has increased in each of the last three quarters, with growth averaging 150.3% over the last six quarters.
  • The strongest year-over-year quarter for Net Equity Issued and Repurchased in the past five years was Q4 2025, with growth of 749.9%; the weakest was Q3 2024, with a decline of 68.8%.
  • According to Business Quant data, Net Equity Issued and Repurchased for the three prior quarters was $11.07 million (Q1 2026), $13.68 million (Q4 2025) and $5.89 million (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Equity Issued (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn -377.00 Mn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn -966.00 Mn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn -5.00 Mn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn -406.00 Mn
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn 4.00 Mn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn -
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn -283.00 Mn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn -
10 NewAmsterdam Pharma 2.30 Bn -236.30 Mn - 5.45 Mn
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2026 5.45 Mn
Jun 30, 2026 11.04 Mn
Mar 31, 2026 11.07 Mn
Dec 31, 2025 13.68 Mn
Sep 30, 2025 5.89 Mn
Jun 30, 2025 3.43 Mn
Mar 31, 2025 8.11 Mn
Dec 31, 2024 1.61 Mn
Sep 30, 2024 58,000.00
Jun 30, 2024 4.66 Mn
Mar 31, 2024 9.20 Mn
Sep 30, 2023 186,000.00
Jun 30, 2023 6.33 Mn
Mar 31, 2023 2.39 Mn
API Access

NewAmsterdam Pharma Net Equity Issued and Repurchased API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=net-equity-issued-and-repurchased&ticker=NAMS&period=max&api_key=YOUR_API_KEY